The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Olutasidenib in post-venetoclax patients with mIDH1 AML.
 
Jorge E. Cortes
Consulting or Advisory Role - Bio-Path Holdings, Inc; Bristol-Myers Squibb; Centessa Pharmaceuticals; Gilead Sciences; Menarini; Novartis; Pfizer; Takeda
Research Funding - Abbvie/Genentech (Inst); Actuate Therapeutics (Inst); Astellas Pharma (Inst); Bio-Path Holdings, Inc (Inst); Bristol-Myers Squibb (Inst); Jazz Pharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); Sellas Life Sciences (Inst); Sun Pharma (Inst); Takeda (Inst)
 
Gary J. Schiller
Stock and Other Ownership Interests - Amgen; Bristol-Myers Squibb; Johnson & Johnson
Consulting or Advisory Role - Abbvie; Agios; Astellas Pharma; Celgene; Incyte; Jazz Pharmaceuticals; Novartis; Ono Pharmaceutical
Speakers' Bureau - Abbvie; Astellas Pharma; Bristol-Myers Squibb; Incyte; Jazz Pharmaceuticals; Karyopharm Therapeutics; Kite, a Gilead company; Sanofi; Stemline Therapeutics
Research Funding - Abbvie; Actinium Pharmaceuticals; Actuate Therapeutics; Agios; Amgen; Arog; Astellas Pharma; AVM Biotechnology; Bristol-Myers Squibb/Celgene; Celator; Constellation Pharmaceuticals; Daiichi Sankyo; Deciphera; Delta-Fly Pharma; ElevateBio; FORMA Therapeutics; Fujifilm; Gamida Cell; Genentech/Roche; Geron; Incyte; Jazz Pharmaceuticals; Karyopharm Therapeutics; Kite, a Gilead company; Mateon Therapeutics; Novartis; Onconova Therapeutics; Ono Pharmaceutical; Pfizer; PrECOG; REGiMMUNE; Samus Therapeutics; Sangamo Bioscience; Sanofi; Sellas Life Sciences; Stemline Therapeutics; Syros Pharmaceuticals; Takeda; Tolero Pharmaceuticals; Trovagene
 
Robert Numerof
Employment - Rigel
Stock and Other Ownership Interests - Rigel
 
Daniel Floryk
Employment - Rigel
Stock and Other Ownership Interests - Rigel
 
Brian Andrew Jonas
Consulting or Advisory Role - Abbvie; BMS; Daiichi Sankyo; Genentech; Gilead Sciences; GlycoMimetics; Kymera; Pfizer; Rigel; Servier
Research Funding - Abbvie (Inst); Amgen (Inst); Aptose Biosciences (Inst); AROG (Inst); BMS (Inst); Celgene (Inst); Daiichi Sankyo (Inst); FORMA Therapeutics (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Glycomimetics (Inst); Hanmi (Inst); Immune-Onc Therapeutics (Inst); Incyte (Inst); Jazz Pharmaceuticals (Inst); Loxo (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst); Sigma-Tau (Inst); Treadwell Therapeutics (Inst)
Other Relationship - Gilead Sciences; GlycoMimetics